Online citations, reference lists, and bibliographies.
← Back to Search

True Radiotracers: Cu-64 Targeting Vectors Based Upon Bombesin Peptide.

T. Hoffman, C. J. Smith
Published 2009 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
True radiotracers: Cu-64 targeting vectors based upon bombesin peptide Timothy J. Hoffman, Charles J. Smith⁎ Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA Department of Radiology, University of Missouri School of Medicine, Columbia, MO 65211, USA Department of Molecular Pharmacology and Physiology, University of Missouri School of Medicine, Columbia, MO 65211, USA Department of Chemistry, University of Missouri, Columbia, MO 65211, USA The Radiopharmaceutical Sciences Institute, University of Missouri School of Medicine, Columbia, MO 65211, USA Department of Internal Medicine, University of Missouri School of Medicine, Columbia, MO 65211, USA University of Missouri Research Reactor Center, University of Missouri, Columbia, MO 65211, USA Received 3 February 2009; received in revised form 9 March 2009; accepted 19 March 2009
This paper references
10.1021/BC034018L
MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue.
B. Rogers (2003)
10.1021/IC00202A019
Crystallographic and Thermodynamic Study of Metal Ion Size Selectivity in the Ligand 1,4,7-Triazacyclononane- N, N',N"-triacetate
M. V. D. Merwe (1985)
10.1002/IJC.2910460226
Characterization, in some human breast cancer cell lines, of gastrin‐releasing peptide‐like receptors which are absent in normal breast epithelial cells
S. Giacchetti (1990)
10.1016/s0021-9258(18)55129-2
Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells.
M. Corjay (1991)
10.1021/CR980451Q
Radiometal-Labeled Agents (Non-Technetium) for Diagnostic Imaging
C. Anderson (1999)
Prostate cancer treatment strategies based on tumor-specific biological principles: future directions.
M. Carducci (1996)
10.1021/JM070204R
Synthesis, characterization and in vivo studies of Cu(II)-64-labeled cross-bridged tetraazamacrocycle-amide complexes as models of peptide conjugate imaging agents.
Jennifer E. Sprague (2007)
Successful imaging of malignant melanoma with technetium-99m-labeled monoclonal antibodies.
J. Eary (1989)
10.1021/BC060281L
Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14).
Gráinne B. Biddlecombe (2007)
10.1073/pnas.0705347104
[64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues
A. Prasanphanich (2007)
10.1016/J.NUCMEDBIO.2005.12.011
Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma.
Yishan Yang (2006)
10.1021/JM030383M
Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes.
C. Boswell (2004)
10.2310/7290.2007.00013
In Vitro and In Vivo Evaluation of Alexa Fluor 680-Bombesin[7–14]NH2 Peptide Conjugate, a High-Affinity Fluorescent Probe with High Selectivity for the Gastrin-Releasing Peptide Receptor
Lixin Ma (2007)
10.1021/bc700396e
Synthesis, Copper(II) Complexation, (64)Cu-Labeling, and Bioconjugation of a New Bis(2-pyridylmethyl) Derivative of 1,4,7-Triazacyclononane.
G. Gasser (2008)
Radiolabeling of antibodies for targeted diagnostics
VP Torchilin (1995)
10.1002/CHIN.198309289
1,4,7‐TRIAZACYCLONONANE‐N,N′,N′′‐TRIACETATE (TCTA), A NEW HEXADENTATE LIGAND FOR DIVALENT AND TRIVALENT METAL IONS. CRYSTAL STRUCTURES OF (CRIII(TCTA)), (FEIII(TCTA)), AND NA(CUII(TCTA))·2NABR·8H2O
K. Wieghardt (1983)
10.1158/0008-5472.CAN-03-3845
Synthesis and Evaluation of Bombesin Derivatives on the Basis of Pan-Bombesin Peptides Labeled with Indium-111, Lutetium-177, and Yttrium-90 for Targeting Bombesin Receptor-Expressing Tumors
Hanwen Zhang (2004)
10.2967/jnumed.107.039487
In Vivo Evaluation and Small-Animal PET/CT of a Prostate Cancer Mouse Model Using 64Cu Bombesin Analogs: Side-by-Side Comparison of the CB-TE2A and DOTA Chelation Systems
J. Garrison (2007)
10.1158/1078-0432.CCR-04-1084
Preparation and Biological Evaluation of Copper-64–Labeled Tyr3-Octreotate Using a Cross-Bridged Macrocyclic Chelator
Jennifer E. Sprague (2004)
Radioimmunodetection in cancer identification.
D. Goldenberg (1992)
10.1007/BF00941992
Second-line treatment of metastatic prostatic carcinoma
D. Newling (2004)
Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors.
F. Forrer (2006)
10.2174/1381612023393828
Technetium labeled small peptide radiopharmaceuticals in the identification of lung cancer.
J. Blum (2002)
Peptide receptor imaging and therapy.
D. Kwekkeboom (2000)
microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
X. Chen (2004)
10.2174/138161207779313768
Copper chelation chemistry and its role in copper radiopharmaceuticals.
T. Wadas (2007)
10.1002/(SICI)1097-0045(19970901)32:4<284::AID-PROS9>3.0.CO;2-J
Target to apoptosis: A hopeful weapon for prostate cancer
D. Tang (1997)
cancer cell lines PC - 3 and DU - 145 : internalization of receptor bound 125 I - ( Tyr 4 ) bombesin by tumor cells
MH Corjay (1994)
Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation.
R. Markwalder (1999)
Radiolabeling of antibodies for targeted diagnostics. In: Torchilin VP, editor. Targeted delivery of imaging agents
AR Fritzberg (1995)
Characterization of high - affinity receptors for bombesin / gastrin releasing peptide on the human
H Reile
10.1089/108497804773391694
Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas.
L. Bodei (2004)
10.1093/ANNONC/11.SUPPL_3.267
Therapeutic use of radiolabelled peptides.
E. Krenning (2000)
10.1021/ic00142a037
1,4,7-Triazacyclononane-N,N',N''-triacetate (TCTA), a new hexadentate ligand for divalent and trivalent metal ions. Crystal structures of [CrIII(TCTA)], [FeIII(TCTA)], and Na[CuII(TCTA)].bul.2NaBr.bul.8H2O
K. Wieghardt (1982)
10.2174/1381612023393891
Small peptide radiopharmaceuticals in the imaging of acute thrombus.
J. Blum (2002)
10.1002/PROS.2990250105
Characterization of high‐affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC‐3 and DU‐145: Internalization of receptor bound 125I‐(Tyr4) bombesin by tumor cells
H. Reile (1994)
10.1007/BF00181765
Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients
E. Krenning (2004)
Imaging tumors with peptide-based radioligands.
T. Behr (2001)
10.1002/(SICI)1099-0682(200003)2000:3<559::AID-EJIC559>3.0.CO;2-J
Study of Copper(II) Polyazamacrocyclic Complexes by Electronic Absorption Spectrophotometry and EPR Spectroscopy
C. Geraldes (2000)
10.1016/j.nucmedbio.2008.11.005
In vitro and in vivo analysis of [(64)Cu-NO2A-8-Aoc-BBN(7-14)NH(2)]: a site-directed radiopharmaceutical for positron-emission tomography imaging of T-47D human breast cancer tumors.
Adam F. Prasanphanich (2009)
10.1021/BC0603788
In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties.
J. J. Parry (2007)
Radiochemical investigations of gastrin-releasing peptide receptor-specific [(99m)Tc(X)(CO)3-Dpr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-Leu-Met-(NH2)] in PC-3, tumor-bearing, rodent models: syntheses, radiolabeling, and in vitro/in vivo studies where Dpr = 2,3-diaminopropionic acid and X = H2O or P(CH2
C. J. Smith (2003)
10.1007/s10549-006-9287-8
MicroPET Imaging of Breast Cancer Using Radiolabeled Bombesin Analogs Targeting the Gastrin-releasing Peptide Receptor
J. J. Parry (2006)
10.1021/IC00071A001
Selectivity of antibody-chelate conjugates for binding copper in the presence of competing metals
D. Kukis (1993)
10.2307/j.ctvzgb86t.9
Cancer
Zachary Hall (1906)
Kinetics of the isotopic exchange between copper(II) and copper(II) 1,4,7-triazacyclononane-N,N',N double-prime triacetate
C. Pippin (1990)
10.1016/S0969-8051(96)00130-8
Copper radionuclides and radiopharmaceuticals in nuclear medicine.
P. Blower (1996)
10.2174/187152007780618207
The bright future of radionuclides for cancer therapy.
J. F. Nijsen (2007)
10.1016/J.SURG.2006.07.030
Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
A. Frilling (2006)
10.1021/JM0103817
Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands.
X. Sun (2002)
10.1016/J.NUCMEDBIO.2005.05.005
Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes.
C. J. Smith (2005)
Metabolically stabilized DOTAbombesin based peptides by amino acid modification in position 11
H Maecke (2004)



This paper is referenced by
10.1016/j.nucmedbio.2014.10.008
Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
J. C. Lim (2015)
10.1371/journal.pone.0044046
Evolution of Bombesin Conjugates for Targeted PET Imaging of Tumors
Hanwen Zhang (2012)
10.1007/s10967-015-4290-3
Preparation and evaluation of a single vial AMBA kit for 68Ga labeling with potential for imaging of GRP receptor-positive cancers
U. Pandey (2015)
Development of Radiolabelled Bombesin Analogues for Imaging Prostate Cancer with SPECT and PET
Z. Yu (2014)
Arsenic-72, 77 as a matched pair radiopharmaceutical for imaging and radiotherapy
Yutian Feng (2018)
10.1007/s10967-019-06418-8
Cellular internalization of a cell-penetrating peptide conjugated gastrin-releasing peptide receptor antagonist
Zhengkun Zhong (2019)
10.1007/s10534-012-9578-y
Development of copper based drugs, radiopharmaceuticals and medical materials
P. Szymański (2012)
Positron-emission tomography (PET) imaging agents for diagnosis of human prostate cancer: agonist vs. antagonist ligands.
P. K. Nanda (2012)
10.1039/c7dt02634j
Peptide-based fibrin-targeting probes for thrombus imaging.
B. L. Oliveira (2017)
10.2967/jnumed.110.082826
In Vitro and In Vivo Evaluation of 64Cu-Labeled SarAr-Bombesin Analogs in Gastrin-Releasing Peptide Receptor–Expressing Prostate Cancer
Kimberly A. Lears (2011)
10.1039/c0dt01075h
The role of coordination chemistry in the development of copper and rhenium radiopharmaceuticals.
P. Donnelly (2011)
(18)F-click labeling of a bombesin antagonist with an alkyne-(18)F-ArBF(3) (-): in vivo PET imaging of tumors expressing the GRP-receptor.
Y. Li (2013)
10.1039/c7cc03198j
Investigation of a new "N2S2O2" chelating agent with high Po(iv) affinity.
Ali Younes (2017)
10.2174/1877912305666150102000549
Nanoconstructs in Targeted Alpha-Therapy
Jan Vlk (2015)
10.4155/fmc.11.14
The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86.
Oluwatayo F. Ikotun (2011)
10.1016/j.nucmedbio.2010.04.016
Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model.
Stephanie R. Lane (2010)
10.1021/bc200539t
New macrobicyclic chelator for the development of ultrastable 64Cu-radiolabeled bioconjugate.
Darpan N Pandya (2012)
10.1002/anie.201105547
Strain-promoted copper-free "click" chemistry for 18F radiolabeling of bombesin.
Lachlan S. Campbell-Verduyn (2011)
10.1002/CPLU.201402031
Synthesis and Characterization of a Stable Copper(I) Complex for Radiopharmaceutical Applications
Ewen Bodio (2014)
10.1002/jlcr.3155
Radiocopper for the imaging of copper metabolism.
R. Hueting (2014)
10.11606/T.85.2012.TDE-24082012-155302
Marcadores moleculares derivados da Bombesina para diagnóstico de tumores por SPECT e PET
P. Pujatti (2012)
10.1016/j.bmc.2018.11.031
Clinical aspects of radiolabeled aptamers in diagnostic nuclear medicine: A new class of targeted radiopharmaceuticals.
Leila Farzin (2019)
10.1016/j.nucmedbio.2011.10.009
Bombesin analogues for gastrin-releasing peptide receptor imaging.
P. K. Nanda (2012)
10.1097/MED.0b013e32833392ac
Radiolabeled regulatory peptides for imaging and therapy
P. K. Nanda (2010)
10.1039/c0dt01599g
Radiometallated peptides for molecular imaging and targeted therapy.
J. D. Correia (2011)
10.1524/ract.2012.1964
Inorganic chemistry in nuclear imaging and radiotherapy: current and future directions
V. Carroll (2012)
10.1016/j.nucmedbio.2011.12.004
In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer.
Jeffrey M. Craft (2012)
10.1016/j.ejmech.2013.10.013
Synthesis and radiopharmacological evaluation of ⁶⁴Cu-labeled bombesin analogs featuring a bis(2-pyridylmethyl)-1,4,7-triazacyclononane chelator.
R. Bergmann (2013)
10.3390/molecules25245993
Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer
Christina Baun (2020)
10.1111/j.1476-5381.2010.01068.x
Biodistribution, pharmacokinetics and metabolism of interleukin‐1 receptor antagonist (IL‐1RA) using [18F]‐IL1RA and PET imaging in rats
C. Cawthorne (2011)
10.1089/cbr.2011.0954
In vitro and in vivo evaluation of melanin-binding decapeptide 4B4 radiolabeled with 177Lu, 166Ho, and 153Sm radiolanthanides for the purpose of targeted radionuclide therapy of melanoma.
B. Ballard (2011)
10.1039/c4dt02977a
Towards the elaboration of new gold-based optical theranostics.
Pierre-Emmanuel Doulain (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar